GLP-1 Medications and Breast Cancer: What the Latest Research Really Means
- Surviving Breast Cancer
- Jun 9
- 5 min read
New research on Ozempic, Wegovy, and other GLP-1 medications is raising questions about breast cancer risk, treatment outcomes, and survivorship. Here’s what patients need to know.
SurvivingBreastCancer.org | By Laura Carfang
GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound are best known for helping people lose weight and improve blood sugar control. Now, researchers are asking a bigger question: could these medications also influence breast cancer risk, treatment tolerance, or long-term outcomes? Early studies presented at ASCO in 2026 and research at the San Antonio Breast Cancer Symposium in 2025 suggest the answer may be promising, but the science is still developing.
For people living with breast cancer or navigating survivorship, this is an important topic. Weight, metabolism, hormone therapy, and inflammation can all affect health after a breast cancer diagnosis, which is why GLP-1 medications are drawing so much attention.
What are GLP-1 medications?
GLP-1 receptor agonists are prescription medicines originally developed to treat type 2 diabetes, and several are now also approved for weight management. They mimic a natural gut hormone called GLP-1, which is released after eating and helps coordinate metabolism in several ways: they slow how quickly food leaves the stomach, increase feelings of fullness in the brain, reduce appetite, and help the pancreas release insulin when blood sugar rises while also lowering glucagon, a hormone that tells the liver to release stored sugar. Together, these effects help improve blood sugar control and reduce calorie intake, which can lead to weight loss over time. Common GLP-1 medications include semaglutide, tirzepatide, and liraglutide, sold under brand names such as Ozempic, Wegovy, Mounjaro, Zepbound, Victoza, and Saxenda.
Why breast cancer researchers are paying attention
Weight and metabolic health matter in breast cancer because excess body fat is linked to higher risk of developing breast cancer after menopause, and it may also affect recurrence, treatment tolerance, and long-term outcomes. That is one reason researchers are watching GLP-1 drugs so closely: if they help people lose weight safely and sustain that loss, they may improve more than just body mass.
Scientists are also looking beyond weight loss. GLP-1 medications may influence inflammation, insulin signaling, and other biologic pathways that could matter for cancer development and progression. Because obesity can drive chronic inflammation, raise insulin levels, and alter the metabolic environment around tumors, researchers are now asking whether GLP-1 drugs may help change those conditions in ways that could affect cancer risk or outcomes, not just body weight.
GLP-1s and hormone receptors
Hormone receptor status is central to breast cancer care because many breast cancers are driven by estrogen or progesterone signals. That is why endocrine therapies such as tamoxifen and aromatase inhibitors are so important for hormone receptor-positive disease.
The current research does not show that GLP-1 drugs directly target estrogen receptors, progesterone receptors, or HER2. Instead, the interest is mostly indirect: GLP-1s may help with weight, insulin resistance, and inflammation, which can shape the metabolic environment in which hormone receptor-positive breast cancers develop or recur. In other words, GLP-1 medications are not being studied as hormone therapy; they are being studied as metabolic medications that may affect outcomes in hormone-sensitive disease.
This is especially relevant for people with hormone receptor-positive breast cancer who are taking endocrine therapy. BreastCancer.org highlighted research suggesting GLP-1 use may help some patients on hormonal therapy lose weight, even though that weight loss may be slower or less dramatic than in the general population. At the same time, the available studies are still early, so GLP-1s should not be viewed as a breast cancer treatment outside a clinical trial.
What the newest studies suggest
At the 2026 ASCO Annual Meeting, Penn researchers reported that women ages 45 to 80 who used GLP-1 medications were about 30% less likely to develop breast cancer than women who did not use them. That result is encouraging, but it was observational, so it shows an association rather than proof of prevention.
Other ASCO-presented research found that people with stage I, II, or III lung, breast, colorectal, or liver cancer who took a GLP-1 drug were less likely to progress to stage IV disease than those who did not take one.
It is important to note that some cancer treatments, including certain chemotherapy drugs and targeted therapies, may not be a good match with GLP-1 medications. Because these drugs can affect how treatment is tolerated and how well it works, your care team will weigh the potential risks and benefits before deciding whether to pause or continue a GLP-1 during cancer treatment.
What we know about weight loss
One of the most familiar effects of GLP-1 medications is weight loss, and that may matter for some people with breast cancer. For patients who are gaining weight during treatment, or who are struggling with weight after treatment, these medications may offer another option to support overall health and wellbeing. Researchers are still studying how this may affect breast cancer outcomes, but for many patients, the most immediate benefits may be feeling more in control of weight, energy, and day-to-day health during and after treatment.
What this does not mean
These findings do not mean that GLP-1 drugs should be used outside of a clinical trial to treat or prevent breast cancer. The current evidence is mostly observational, and people with prior cancer were often excluded from the large trials that led to GLP-1 approvals.
It also does not mean that GLP-1 medications are right for everyone with breast cancer. The best choice depends on cancer subtype, current treatment, medical history, weight goals, diabetes status, side effects, and insurance coverage.
Questions to ask your care team
If you are considering a GLP-1 medication, these questions can help guide a conversation with your care team:
Is a GLP-1 medication appropriate for my situation?
Could it help me if I am struggling with weight gain during or after treatment?
Are there any concerns with my cancer subtype or current therapy?
What side effects should I watch for?
How will we know whether the benefits outweigh the risks for me?
Why this story matters now
Even though evidence is still early and more research is needed, GLP-1 medications are now part of a broader conversation about cancer prevention, survivorship, treatment tolerance, and long-term health after breast cancer. For those navigating a breast cancer diagnosis, there is hope but also caution—especially until larger studies can confirm which patients may benefit most and when these medications are safest to use.
Note: This article offers general information and does not replace professional medical advice. Make sure to discuss your options with your healthcare provider.
Read More:
On the Podcast: Breast Cancer Conversations
The Prehab Plan Surgeons Wish You’d Start
